Raymond James maintains Strong Buy on ProQR stock, $14 target

Published 14/03/2025, 18:12
Raymond James maintains Strong Buy on ProQR stock, $14 target

On Friday, Raymond (NSE:RYMD) James reiterated its Strong Buy rating and $14.00 price target for ProQR Therapeutics N.V. (NASDAQ:PRQR), highlighting the company’s promising clinical developments and solid financials following its fourth-quarter earnings report for 2024. According to InvestingPro data, analyst targets range from $4 to $15, though the stock has faced headwinds, declining 34% year-to-date. ProQR, a biotechnology firm focused on RNA therapies for severe genetic disorders, has recently demonstrated clinical progress with its Axiomer platform.

The lead candidate from this platform, AX-0810, is being developed to treat cholestatic diseases by targeting NTCP. Initial data from this study is expected in the fourth quarter of 2025. Additionally, ProQR has outlined plans to initiate clinical studies for three more candidates: AX-1412 for cardiovascular disease, AX-2402 for Rett Syndrome, and AX-2911 for MASH, with top-line data anticipated in 2026.

The company’s collaboration with the Rett Syndrome Research Trust has been expanded, providing up to $9.2 million to support the development of AX-2402. ProQR also appointed Dr. Peter A. Beal as Chief ADAR scientist, enhancing its research capabilities.

Financially, ProQR reported collaboration revenue of €4.3 million and operating expenses of €14.5 million for the fourth quarter of 2024. The earnings per share (EPS) was reported at €(0.09). As of the end of the fourth quarter, ProQR’s cash and cash equivalents stood at €149.4 million. This includes approximately €71.6 million from recent financing completed on October 25, 2024. The company anticipates its cash runway to extend into mid-2027, providing a stable financial foundation for ongoing and future research activities. InvestingPro analysis reveals the company maintains a healthy current ratio of 3.95, though it’s quickly burning through cash with negative free cash flow of $35.5 million in the last twelve months. Get access to 10+ additional ProTips and comprehensive financial metrics with InvestingPro’s detailed research report.

In other recent news, ProQR Therapeutics N.V. has seen notable developments. Citi analysts upgraded ProQR’s stock rating from Neutral to Buy, setting a price target of $4.00. This decision was influenced by the market’s minimal valuation of ProQR’s leading drug candidate, AX-0810, which targets cholestatic diseases. Meanwhile, Jones Trading initiated coverage with a Buy rating and a more optimistic price target of $11.00. Jones Trading highlighted ProQR’s focus on RNA editing and its potential in treating both rare and common diseases. They also noted the anticipated release of Phase 1 data for the PSC program in 2025, which could demonstrate the company’s RNA editing capabilities. Furthermore, the collaboration with Eli Lilly (NYSE:LLY) was acknowledged as a significant asset, suggesting potential milestone payments. Both analyst firms have expressed a positive outlook on ProQR’s future, given its strategic focus and pipeline advancements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.